Cargando…

Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals

Convalescent plasma therapy, which involves administering plasma from recovered coronavirus disease 2019 (COVID-19) patients to infected individuals, is being explored as a potential treatment for severe cases of COVID-19. This study aims to evaluate the efficacy and safety of convalescent plasma th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terada, Mari, Saito, Sho, Kutsuna, Satoshi, Kinoshita-Iwamoto, Noriko, Togano, Tomiteru, Hangaishi, Akira, Shiratori, Katsuyuki, Takamatsu, Yuki, Maeda, Kenji, Ishizaka, Yukihito, Ohtsu, Hiroshi, Satake, Masahiro, Mitsuya, Hiroaki, Ohmagari, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671928/ https://www.ncbi.nlm.nih.gov/pubmed/38004324 http://dx.doi.org/10.3390/life13112184

Ejemplares similares

Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma
por: Inada, Makoto, et al.
Publicado: (2023)

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)
por: Tomita, Noriko, et al.
Publicado: (2022)

The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan
por: Kamo-Imai, Ayumi, et al.
Publicado: (2023)

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
por: Suzuki, Tetsuya, et al.
Publicado: (2023)

Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
por: Inada, Makoto, et al.
Publicado: (2022)

The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan
por: Togano, Tomiteru, et al.
Publicado: (2021)

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
por: Saito, Sho, et al.
Publicado: (2023)

Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies
por: Inada, Makoto, et al.
Publicado: (2021)

SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19
por: Kutsuna, Satoshi, et al.
Publicado: (2021)

Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination
por: Okumura, Nobumasa, et al.
Publicado: (2022)

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants
por: Tsuchiya, Kiyoto, et al.
Publicado: (2023)

Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan
por: Hara, Hisao, et al.
Publicado: (2021)

Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan
por: Suzuki, Tetsuya, et al.
Publicado: (2022)

Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan
por: Terada, Mari, et al.
Publicado: (2021)

480. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant among Immunocompromised Patients
por: KAMEGAI, K O H E I, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
por: Maeda, Kenji, et al.
Publicado: (2021)

First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics
por: Saito, Sho, et al.
Publicado: (2021)

We Should Pay More Attention to Sex Differences to Predict the Risk of Severe COVID-19: Men Have the Same Risk of Worse Prognosis as Women More Than 10 Years Older
por: Matsushita, Yumi, et al.
Publicado: (2023)

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan
por: Okumura, Nobumasa, et al.
Publicado: (2022)

Considerations and concerns regarding the readiness to remove face coverings
por: Terada, Mari, et al.
Publicado: (2022)

No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity
por: Nomoto, Hidetoshi, et al.
Publicado: (2021)

Possibility of transmission of severe acute respiratory syndrome coronavirus 2 in a tertiary care hospital setting: A case study
por: Morioka, Shinichiro, et al.
Publicado: (2020)

Difficulty of downscaling the precautions for coronavirus disease-19 based on negative throat polymerase chain results in the early phase of infection()
por: Suzuki, Tetsuya, et al.
Publicado: (2020)

A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection
por: Beppu, Hiroko, et al.
Publicado: (2022)

Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019
por: Miyazato, Yusuke, et al.
Publicado: (2020)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Predicting respiratory failure for COVID-19 patients in Japan: a simple clinical score for evaluating the need for hospitalisation
por: Yamada, Gen, et al.
Publicado: (2021)

A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
por: Miyazato, Yusuke, et al.
Publicado: (2022)

Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities
por: Tomidokoro, Daiki, et al.
Publicado: (2023)

Surveillance and risk assessment of health screening for vaccine-preventable diseases among international students in Japan: A cross-sectional study in 2020
por: Takahata, Hanako, et al.
Publicado: (2022)

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
por: Miyazato, Yusuke, et al.
Publicado: (2022)

Meningoencephalitis Caused by a Campylobacter fetus in a Patient with Chronic Alcoholism
por: Tanabe, Sho, et al.
Publicado: (2019)

Reply to “Initial Narrow- or Broad-spectrum Treatment for Meningoencephalitis”
por: Tanabe, Sho, et al.
Publicado: (2019)

Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 panel, a rapid multiplex PCR method for the diagnosis of COVID-19
por: Ishikane, Masahiro, et al.
Publicado: (2022)

Factors associated with development and persistence of post-COVID conditions: A cross-sectional study()
por: Miyazato, Yusuke, et al.
Publicado: (2022)

Periungual desquamation in a Japanese Adult recovering from severe COVID-19
por: Nakamoto, Takato, et al.
Publicado: (2021)

Hemoptysis and a Newly Formed Lung Bulla in a Case of Convalescent COVID-19 Pneumonia
por: Sato, Lubna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9csahks33krkq80accct5j67jc